Inflammatory Markers in Recent Onset Psychosis and Chronic Schizophrenia

Schizophrenia Bulletin

Volumn 42, Issue 1, 2016, Pages 134-141

  Dickerson, Faith ^a   Stallings, Cassie ^a   Origoni, Andrea ^a   Schroeder, Jennifer ^b   Katsafanas, Emily ^a   Schweinfurth, Lucy ^a   Savage, Christina ^a   Khushalani, Sunil ^a   Yolken, Robert ^c  

^a Stanley Research Program at Sheppard Pratt   (United States)

^b Schroeder Statistical Consulting   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunity; inflammation; psychosis; schizophrenia

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CASEIN; FUNGUS ANTIBODY; GLIADIN; IMMUNOGLOBULIN G; PENTRAXIN 3; SERUM AMYLOID P;

ADOLESCENT; ADULT; AGED; CASE CONTROL STUDY; CHRONIC DISEASE; FEMALE; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; MIDDLE AGED; PSYCHOSIS; SACCHAROMYCES CEREVISIAE; SCHIZOPHRENIA; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIBODIES, FUNGAL; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CASEINS; CHRONIC DISEASE; FEMALE; GLIADIN; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SACCHAROMYCES CEREVISIAE; SCHIZOPHRENIA; SERUM AMYLOID P-COMPONENT; TIME FACTORS; YOUNG ADULT;

EID: 84954308835     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv108     Document Type: Article

References (43)

1. Suvisaari J, Loo BM, Saarni SE, et al. Inflammation in psychotic disorders: A population-based study. Psychiatry Res. 2011;189:305-311.
2. Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: an overview. Psychiatry Res. 2014;216:277-285.
3. Müller N. Immunology of schizophrenia. Neuroimmunomodulation. 2014;21:109-116.
4. Müller N, Myint AM, Schwarz MJ. Inflammation in schizophrenia. Adv Protein Chem Struct Biol. 2012;88:49-68.
5. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry. 2013;73:951-966.
6. Kinney DK, Hintz K, Shearer EM, et al. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med Hypotheses. 2010;74:555-563.
7. Miller BJ, Culpepper N, Rapaport MH, Buckley P. Prenatal inflammation and neurodevelopment in schizophrenia: A review of human studies. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:92-100.
8. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year populationbased register study. Am J Psychiatry. 2011;168:1303-1310.
9. Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry. 2014;75:300-306.
10. Corvin A, Morris DW. Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. Biol Psychiatry. 2014;75:276-283.
11. Dickerson F, Stallings C, Origoni A, et al. C-reactive protein is elevated in schizophrenia. Schizophr Res. 2013;143:198-202.
12. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: A review and meta-analysis. Clin Schizophr Relat Psychoses. 2014;7:223-230.
13. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157-183.
14. Dickerson F, Stallings C, Origoni A, et al. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol Psychiatry. 2010;68:100-104.
15. Severance EG, Dickerson FB, Halling M, et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res. 2010;118:240-247.
16. Severance EG, Alaedini A, Yang S, et al. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr Res. 2012;138:48-53.
17. First M, Gibbon, M, Spitzer, RL, Williams, JBW. Structured Clinical interview for DSM-IV Disorders, Non-Patient Edition. New York, NY: Biometrics Research; 1998.
18. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310-319.
19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
20. Fidell BTL. Using Multivariate Statistics (4th Edition). Boston, MA: Allyn and Bacon; 2001.
21. Rubin D. Multiple imputation after 18+ years. J Am Stat Assoc. 1996;91:473-489
22. Jones KA, Thomsen C. The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci. 2013;53:52-62.
23. Li Y, Zhou K, Zhang Z, et al. Label-free quantitative proteomic analysis reveals dysfunction of complement pathway in peripheral blood of schizophrenia patients: evidence for the immune hypothesis of schizophrenia. Mol Biosyst. 2012;8:2664-2671.
24. Carty M, Reinert L, Paludan SR, Bowie AG. Innate antiviral signalling in the central nervous system. Trends Immunol. 2014;35:79-87.
25. Lin CW, Chen CY, Cheng SJ, Hu HT, Hsueh YP. Sarm1 deficiency impairs synaptic function and leads to behavioral deficits, which can be ameliorated by an mGluR allosteric modulator. Front Cell Neurosci. 2014;8:87.
26. Pothlichet J, Quintana-Murci L. The genetics of innate immunity sensors and human disease. Int Rev Immunol. 2013;32:157-208.
27. Huang E, Wells CA. The ground state of innate immune responsiveness is determined at the interface of genetic, epigenetic, and environmental influences. J Immunol. 2014;193:13-19.
28. Kang WS, Park JK, Lee SM, Kim SK, Park HJ, Kim JW. Association between genetic polymorphisms of Toll-like receptor 2 (TLR2) and schizophrenia in the Korean population. Gene. 2013;526:182-186.
29. Smyth AM, Lawrie SM. The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci. 2013;11:107-117.
30. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry. 2001;58:1032-1037.
31. Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry. 2005;162:767-773.
32. Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry. 2007;61:688-693.
33. Atmaca HT, Kul O, Karakuş E, Terzi OS, Canpolat S, Anteplioʇlu T. Astrocytes, microglia/macrophages, and neurons expressing Toll-like receptor 11 contribute to innate immunity against encephalitic Toxoplasma gondii infection. Neuroscience. 2014;269:184-191.
34. Beiting DP, Peixoto L, Akopyants NS, et al. Differential induction of TLR3-dependent innate immune signaling by closely related parasite species. PLoS One. 2014;9:e88398.
35. Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol. 2014;14:109-121.
36. Cooley ID, Chauhan VS, Donneyz MA, Marriott I. Astrocytes produce IL-19 in response to bacterial challenge and are sensitive to the immunosuppressive effects of this IL-10 family member. Glia. 2014;62:818-828.
37. Poggi A, Zocchi MR. NK cell autoreactivity and autoimmune diseases. Front Immunol. 2014;5:27.
38. Rubicz R, Yolken R, Alaedini A, et al. Genome-wide genetic and transcriptomic investigation of variation in antibody response to dietary antigens. Genet Epidemiol. 2014;38:439-446.
39. Shastri A, Bonifati DM, Kishore U. Innate immunity and neuroinflammation. Mediators Inflamm. 2013;2013:342931.
40. Brown AS, Hooton J, Schaefer CA, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004;161:889-895.
41. Gardner RM, Dalman C, Wicks S, Lee BK, Karlsson H. Neonatal levels of acute phase proteins and later risk of nonaffective psychosis. Transl Psychiatry. 2013;3:e228.
42. Dickerson F, Stallings C, Origoni A, Schroeder J, Khushalani S, Yolken R. Mortality in schizophrenia: clinical and serological predictors. Schizophr Bull. 2014;40:796-803.
43. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.